Receptor tyrosine kinase inhibitors with numerous targets, which include VEGF, have activity in RCC, hepatocellular carcinoma, gastrointestinal stromal tumors, and other malignancies. This evidence concerns the gene VEGFA and renal cell adenocarcinoma.